(Q38102783)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Clinical application of regulatory T cells in type 1 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Piotr Trzonkowski

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

Natalia Marek-Trzonkowska

29 February 2020

series ordinal

1

object named as

Natalia Marek-Trzonkowska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Małgorzata Myśliwec

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

30 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

322-332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

How regulatory T cells work

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

T cell-mediated modulation of mast cell function: heterotypic adhesion-induced stimulatory or inhibitory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD4+CD25+ T Cells Lyse Antigen-Presenting B Cells by Fas-Fas Ligand Interaction in an Epitope-Specific Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Novel role of regulatory T cells in limiting early neutrophil responses in skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

The regulatory T cell family: distinct subsets and their interrelations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Mechanisms of foxp3+ T regulatory cell-mediated suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Multiple immuno-regulatory defects in type-1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

New reagents on the horizon for immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Regulatory T cells overturned: the effectors fight back

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Increased spontaneous production of VEGF by CD4+ T cells in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Oral tolerance to insulin and the insulin B-chain: cell lines and cytokine patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD3-specific antibodies: a portal to the treatment of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Interleukin-2 and regulatory T cells in graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Impact of blood amylase peak over vascular graft thrombosis in pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Islet transplantation in patients with diabetes mellitus: choice of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation in the absence of GAD and IA-2 autoantibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

The time is crucial for ex vivo expansion of T regulatory cells for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Concise review: pancreas regeneration: recent advances and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

Improvement in outcomes of clinical islet transplantation: 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

High regulatory T-cell levels at 1 year posttransplantation predict long-term graft survival among kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

CD4(+)FoxP3(+) regulatory T-cells in human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12029

21 January 2018

Identifiers

DOI

10.1111/PEDI.12029

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23627860%20AND%20SRC:MED&resulttype=core&format=json